Citations

Clear

9383 citation(s) found for "Thomas, PS".

Validation of 13,102 ICD-10-CM Codes Using a Large Language Model-Based System
Wang, Yichen, Song, Yilin , Siu, Rex K. , Nimma, Induja R., Yan, Yan, Savage, Thomas , Wang, Yiming, Li, Zhichen, Ramai, Daryl , Wang, Jiale , Badurdeen, Dilhana, Tao, Cui, Kumbhari, Vivek , Huang, Yuting, Huang, Yuting , Huang, Yuting , Wang, Jiale

Mayo Clinic

No container title available | December 31, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.30.25343244 Get It

ABSTRACT Objective To comprehensively evaluate the validity of ICD-10-CM codes for both prevalent diagnoses and less common diseases, and to assess the performance of a large language model (LLM)-based system in validating these codes. Materials and Methods This retrospective study analyzed hospital admissions from the Medical Information Mart for Intensive Care (MIMIC-IV) database. We developed a validated LLM-based system using GPT-4o, refined through iterative prompt engineering, to assess ICD-10-CM code validity. We measured the PPV of ICD-10-CM codes, PPV of principal and secondary diagnoses, and the performance of an LLM-based system in code validation. Results Among 865,079 assigned codes, the PPV was 84.6% (95% CI, 84.5%-84.6%). Principal diagnoses had a PPV of 93.9% (95% CI, 93.7%-94.1%), while secondary diagnoses had a PPV of 83.8% (95% CI, 83.7%-83.9%). The LLM system demonstrated high performance in validating ICD codes, achieving 93.6% accuracy, 95.4% sensitivity and 85.2% specificity. Among correctly assigned secondary diagnoses, the majority (67.9%) represented historical or baseline conditions, while 32.1% reflected active conditions that deviated from baseline status; 22.3% of these emerged after hospital admission. PPV decreases with later diagnosis positions, with the largest decline occurring between principal and secondary diagnoses. Discussion and Conclusion In this large-scale evaluation, ICD-10-CM codes exhibited generally high accuracy, though variability existed by position and condition type. A validated LLM system performed comparably to physician review and offers a scalable means to improve coding accuracy. These findings support the potential for integrating LLM-based auditing into routine workflows to strengthen the quality of administrative and research data.
Correlation of EZH2 and related signaling molecules p-STAT3, p-ERK1/2, and MYC overexpression with H3K27 trimethylation associates differently to disease progression in JAK2 mutation -positive and -negative myeloid neoplasms
Flerova, Elizaveta , Chai, Jiani , Gong, Jerald Z., Wang, Yanhua, Tian, Xuejun , Choudhuri, Jui

Mayo Clinic

Leukemia & Lymphoma | December 31, 2025 | Volume: 67 | Issue: 4 | Pages: 832-845

10.1080/10428194.2025.2609752 | PMID 41474263 Get It

Extensive coronary-cameral fistulas and incidental left ventricular papillary fibroelastoma
Almani, Muhammad Usman , AHLUWALIA, VIBHOR, STEMPNIEWICZ, PETER, Chamoun, Antonio J., Ahluwalia, Vibhor, Yousuf, Muhammad , Alzubi, Jafar

Mayo Clinic

BMJ Case Reports | December 31, 2025 | Volume: 18 | Issue: 12 | Pages: e269899

10.1136/bcr-2025-269899 | PMID 41475864 Get It

We report the rare coexistence of extensive coronary-cameral fistulas (CCFs) with aneurysmal dilatation of coronary arteries and an incidental left ventricular papillary fibroelastoma (PFE) in a female in her early 70s who presented with chest pain and lower extremity oedema. Multimodality imaging, including transoesophageal echocardiography, cardiac CT and coronary angiography, confirmed the diagnosis. The PFE was surgically resected to prevent embolic complications, while the CCFs were managed conservatively due to their haemodynamic insignificance. This case demonstrates that even extensive CCFs may be haemodynamically insignificant, while a small PFE can pose a significant embolic threat, justifying disparate management strategies guided by multimodality imaging and haemodynamic assessment.
A Randomized, Double-Blind, Controlled, Parallel Group Study with Amustaline/Glutathione Pathogen Reduced Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS Study): -- Protocol for a Phase 3, Randomized, C
Ayala, Edgardo F. Cartagena, Colon, Lumen Vera, Aydinok, Y., Arboleda-Osorio, Bolivar , Bracey, Arthur , Fasano, Ross M. , Yee, Marianne, Zubair, Abba, Nizzi, Frank, Shah, Sanjay, Snyder, Edward L. , Treml, Angela , Zheng, Yan, Takemoto, Clifford M., Green, Jeffrey A., Jackson, Bryon , Gniadek, Thomas J. , Bentow, Stanley, Mufti, Nina, Aydınok, Yeşim , Fasano, Ross M. , Sarode, Ravi , Pitman, John P. , Liu, Kathy , Corash, Laurence M , Benjamin, Richard J

Mayo Clinic

No container title available | December 31, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7801515/v1 Get It

Abstract Background Red blood cell (RBC) transfusion may be lifesaving, however transfusion-transmitted infections (TTI) and transfusion-associated graft-versus-host disease (TA-GVHD) still pose a threat despite current donor selection and testing requirements. Amustaline (S-303)/glutathione (GSH) pathogen reduction (PR) is designed to inactivate infectious microbes and leukocytes in RBCs. The RedeS study evaluates the safety and efficacy of amustaline/GSH PR-RBCs compared to conventional RBCs in a broad spectrum of patients requiring acute and/or repeated RBC transfusion support. Methods RedeS is a Phase 3, prospective, multi-center, randomized, double-blind, active-controlled, parallel-design study, with a 6-month extension option to evaluate patients requiring repeated transfusions including red cell exchange (RCE).Eligible subjects will be stratified according to site, baseline bleeding status and participation in the extension period. The study arms include a transfusion period of 28-days for anemia with any bleeding or non-bleeding patients or a 28-day+6-month extension for non-bleeding patients with chronic anemia requiring repeated simple transfusions, or for patients with sickle cell disease (SCD) expected to receive three RCE procedures. The study will seek to enroll 600-800 subjects in the overall safety analysis, including ~140 repeatedly-transfused subjects in the 6-month extension including up to 30 subjects receiving three RCE procedures. The primary safety endpoints are the proportion of patients with any treatment-emergent adverse events (TEAEs) related to study RBC transfusion through 28 days after the last study transfusion, and the proportion of patients with treatment-emergent antibodies with confirmed specificity to PR-RBCs. The primary efficacy endpoint is the hemoglobin (Hb) increment in subjects who are non-bleeding at baseline, adjusted for the grams of Hb transfused and averaged over multiple transfusions. With 352 evaluable transfused non-bleeding subjects (176 per treatment group) from either arm, the study will have 80% power to demonstrate non-inferiority, defined as a Hb increment treatment difference of no more than 15% of the Control group mean, assuming a Control arm coefficient of variation of 50%. Discussion RedeS will characterize the safety of amustaline/GSH PR-RBCs and is designed to demonstrate the non-inferiority of PR-RBCs to conventional RBCs with respect to Hb increment, a common pragmatic clinical assessment of RBC transfusion effectiveness.
The E-AHPBA—ESSO—Innsbruck consensus recommendations on peri- and postoperative management following liver resection
Maier, Eva , Stättner, Stefan, Carrión-Álvarez, Lucía , Martino, Marcello Di, Primavesi, Florian, Sochorová, Dana , Laarhoven, Stijn van , Balakrishnan, Anita, Buis, Carlijn I. , Cipriani, Federica, Erdmann, Joris, Frampton, A., Fuks, David, Melloul, Emmanuel, Oberkofler, Christian E. , Petritsch, Stefan, Raab, Helmut, Rahbari, Nuh N. , Rappold, Daniela , Ruzzenente, Andrea, Schäfer, Benedikt , Serrablo, Alejandro, Soreide, Kjetil, Ernesto, Sparrelid, Starlinger, Patrick P, Tinguely, Pascale, Dasari, Bobby V M, Donadon, Matteo, Dopazo, Cristina, Gruenberger, T., Jonas, E G, Malik, Hassan, Siriwardena, Ajith K, Braunwarth, Eva , Di Martino, Marcello , Olthof, Pim , van Laarhoven, Stijn , Cipriani, Federica , Erdmann, Joris I , Lancellotti, Francesco , Oberkofler, Christian , Sallinen, Ville , Søreide, Kjetil , Starlinger, Patrick , Aldrighetti, Luca , Donadon, Matteo , Dopazo, Cristina , Gruenberger, Thomas , Viganó, Luca , Maglione, Manuel , Stättner, Stefan , Primavesi, Florian , Breitkopf, Robert , Fuks, David , Gilg, Stefan , Gulla, Aistė , Margreiter, Christian , Reiberger, Thomas , Ruzzenente, Andrea , Schaefer, Benedikt, Schnitzbauer, Andreas A. , Søreide, Kjetil , Sparrelid, Ernesto , Starlinger, Patrick , Stavrou, Gregor Alexander , Aldrighetti, Luca , Dasari, B. , Gruenberger, Thomas , Jonas, Eduard , Malik, Hassan , Siriwardena, Ajith K. , Maglione, Manuel

Mayo Clinic

British Journal of Surgery | December 30, 2025 | Volume: 113 | Issue: 1 | Pages: No page available

10.1093/bjs/znaf272 | PMID 41467576 Get It

Abstract Background Liver surgery carries a high risk of complications due to the complex interplay of patient-related factors, disease characteristics, and liver function. Expertise is essential for healthcare professionals managing hepatobiliary patients. This European consensus provides evidence-based guidance on selected aspects of peri- and postoperative care. Methods A modified Delphi process was used to achieve consensus, with a 70% agreement threshold. The expert panel comprised hepatobiliary surgeons, anaesthetists, hepatologists, a specialist nurse, and a physiotherapist. A systematic literature search was conducted in PubMed/MEDLINE, Embase, Web of Science, and Cochrane databases. Six topics were addressed: thromboprophylaxis; perioperative antibiotics; prehabilitation/nutrition/mobilization; bile leak including bilioenteric anastomosis leaks; post-hepatectomy haemorrhage; and post-hepatectomy liver failure (PHLF). Evidence appraisal and statement development followed Scottish Intercollegiate Guidelines Network methodology. A patient representative reviewed the guideline. Results Searching the literature yielded 204 included publications from an initial 6514. Thirty-two statements were formulated with a median evidence level of 2. Evidence strength varied by topic with noticeably lower evidence levels in complex surgery settings and less prevalent conditions. In some topics, study heterogeneity and specific inclusion criteria resulted in conditional recommendations, despite high-level evidence. Notably, the weakest evidence was found for perioperative thromboprophylaxis and PHLF management. Strong recommendations were formulated for prehabilitation, early postoperative mobilization, and avoidance of routine drain use. Several evidence gaps warranting multicentre studies were identified. Conclusion Optimizing peri- and postoperative care after liver resection remains challenging. Standardizing key practices and addressing evidence gaps through collaborative research are vital to improve outcomes.
Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single‐Institution Experience at Mayo Clinic
Alnughmush, Ahmed , Atallah‐Yunes, Suheil Albert , Hellou, Tamer , Habermann, Thomas M., Wang, Yucai, Munoz, Javier, Madiha, Iqbal, King, R., Breen, William G. , Villasboas, Jose C., Witzig, Thomas E., Ansell, S. M., Nowakowski, Grzegorz S. , Habermann, Thomas M. , Habermann, Thomas , Atallah-Yunes, Albert , Witzig, T.E. , Ansell, Stephen M.

Mayo Clinic

American Journal of Hematology | December 30, 2025 | Volume: 101 | Issue: 3 | Pages: 639-643

10.1002/ajh.70178 | PMID 41462033 Get It

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors
Alexander, S P H , Fabbro, Doriano , Peach, Chloe J. , Gibb, Alasdair J. , Kelly, Eamonn , Mathie, Alistair , Veale, Emma L. , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Beuve, Annie, Brouckaert, Peter, Burnett, John C., Friebe, Andreas, Garthwaite, John, Hobbs, Adrian J., Koesling, Doris, Kuhn, Michaela, Leitinger, Birgit , Potter, Lincoln R., Russwurm, Michael, Schmidt, Harald H. H. W., Stasch, Johannes‐Peter, Waldman, Scott A., Alexander, Stephen P H , Mathie, Alistair A , Southan, Christopher , Davies, Jamie A , Bryant, Clare , Farndale, Richard W , Jarvis, Gavin E , Kilpatrick, Laura , Leitinger, Birgit , MacEwan, David , Monie, Tom P , Veale, Emma L , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Peach, Chloe J. , Gibb, Alasdair J. , Kelly, Eamonn , Beuve, Annie , Brouckaert, Peter, Burnett, John C., Farndale, Richard, Friebe, Andreas , Garthwaite, John, Hobbs, Adrian J., Koesling, Doris , Kuhn, Michaela, Potter, Lincoln R., Russwurm, Michael, Schmidt, Harald , Stasch, Johannes‐Peter, Waldman, Scott A.

Mayo Clinic

British Journal of Pharmacology | December 30, 2025 | Volume: 182 | Issue: S1 | Pages: No page available

10.1111/bph.70233 | PMID 41461584 Get It

The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear, accessible, and well‐structured, rather than the scope of the content, which spans approximately 500 pages. The Concise Guide summarises the key pharmacological properties of around 1900 human drug targets, and nearly 7000 interactions, involving around 4400 ligands. While the content is a substantially condensed version of the more detailed information and links available at the www.guidetopharmacology.org website, the printed guide serves as a permanent, citable, point‐in‐time record, that remains stable despite ongoing updates to the online database. The full contents of this publication can be found at https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70233 . The Concise Guides provide expert‐curated recommendations of ‘Gold Standard’ selective pharmacological tools, available either commercially or as donations, which enable the identification of individual drug targets or families of drug targets. While the Concise Guide offers a more streamlined overview, more comprehensive information, including detailed pharmacological profiles and links to multiple online databases, is available through the Guide to Pharmacology website. The 2025/26 edition of the Concise Guide is based on material current as of mid‐2025, and supersedes all previous editions, including the 2023/24 Guide, and earlier Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), and as such provides official IUPHAR classification and nomenclature for human drug targets, where applicable. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. Each section includes nomenclature guidance, concise summaries, information of the best available pharmacological tools, key references, and suggestions for further reading.
A conditional two‐step approach for detecting Lewy Body pathology: smell function testing and α‐synuclein seed amplification
Mastenbroek, Sophie E , Collij, Lyduine E., Caldera, Serena, Serrano, Geidy E, Adler, Charles, Vargiu, Claudia Marina , Palmqvist, Sebastian, Barkhof, Frederik, Beach, Thomas G, Hansson, Oskar H., Collij, Lyduine , Vogel, Jacob W. , Serrano, Geidy E. , Adler, Charles, Palmqvist, Sebastian , Barkhof, Frederik , Parchi, Piero , Beach, Thomas G. , Ossenkoppele, Rik , Hansson, Oskar

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_102894 Get It

Abstract Background Cerebrospinal fluid (CSF) seed amplification assays (SAAs) for detecting α‐synuclein (αsyn) seeds have recently emerged as robust in vivo biomarkers of Lewy body pathology (LBP). However, CSF sampling is invasive, costly, and time‐consuming, limiting its widespread use. We aimed to develop and evaluate a neuropathologically‐validated two‐step workflow, leveraging smell function and CSF αsyn SAA to accurately determine postmortem LBP status. This approach could reduce the number of confirmatory lumbar punctures needed (Figure 1). Methods The study included 358 individuals from the Arizona Study of Aging and Neurodegenerative Disorders with antemortem smell testing, CSF αsyn SAA results, and postmortem neuropathological assessments of regional LBP burden. Step‐1 of the two‐step workflow involved a risk‐stratification model predicting postmortem cortical LBP‐positivity (LBP ctx , defined as at least mild pathology in any cortical region) using logistic regression models with University of Pennsylvania Smell Identification Test (UPSIT) scores (smell testing), age, and sex as predictors. In step‐2, confirmatory CSF αsyn SAA testing was applied only to participants identified as high‐risk in step‐1. Workflow performance ‐ accuracy, positive predictive value (PPV), negative predictive value (NPV), and reduction in CSF testing ‐ was evaluated in (i) the entire study cohort; (ii) patients with clinical parkinsonism; (iii) patients with an Alzheimer's disease (AD) clinical syndrome; and (iv) clinically unimpaired (CU) individuals. Results Participants had a mean age at death of 86.2±7.8 years, 42.6% were female, 35.2% had LBP ctx , and the average time between UPSIT and death was 3.2±2.3 years (Table 1). Using a 95% sensitivity cut‐off for the UPSIT‐based algorithm, the two‐step workflow achieved high accuracy in identifying LBP ctx (whole cohort=94%; clinical parkinsonism=95%; clinical AD=94%; CU=93%; Figure 2a), while reducing CSF testing (whole cohort=‐43%; clinical parkinsonism=‐23%; clinical AD=‐35%; and CU=‐80%; Figure 2d). PPVs ranged from 75‐96% and were highest in the clinical parkinsonism subgroup (96%) where LBP ctx + was highest (62.7%). NPVs ranged between 95‐98% and were highest in the clinical AD subgroup (98%) (Figure 2b‐c). The two‐step approach reached accuracies similar to using CSF tests in all participants. Conclusions Implementing a two‐step workflow in different clinical scenarios may reduce invasive testing with CSF, minimizing the burden for individuals and costs for healthcare providers.
Electronic Memory Support System (eMSS): An Innovative Digital Calendar and Training Program for Older Adults with Mild Cognitive Impairment
McClymont, Shekinah, Berbatovci, Fjolla , Schwellnus, Meg, Santos, Octavio A. , Chan, Adrian D. C. , Chandler, Melanie , Shandera‐Ochsner, Anne L., Jaiswal, Atul, Trudel, Chantal , Thomas, Neil , Rajabiyazdi, Fateme , Locke, Dona E.C.

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S4 | Pages: No page available

10.1002/alz70858_107207 Get It

Abstract Background Individuals with mild cognitive impairment (MCI) experience challenges in maintaining independence in their instrumental activities of daily living (IADLs). The memory support system (MSS) is a paper‐based planner intervention to train individuals with MCI to complete personal goals and IADLs independently. As more individuals use electronic calendar systems, the MSS will need to adapt. This project aimed to develop and test an electronic prototype of the MSS (eMSS). Method Drawing on the MSS, an eMSS prototype intended for phone/tablet use was developed in Axure, allowing participants to interact with the planner and its sections (calendar, notes, to do list). The prototype was evaluated with MSS trainers and individuals with MCI and their partners using a computer or tablet over a virtual platform. Participants were asked to go through fictional ‘planning’ scenarios which were assessed using cognitive task analysis (CTA). The scenarios were designed to evaluate overall ease of use, and specifics such as navigation between pages/sections and developing schedules and task lists. During sessions, participants were encouraged to 'think aloud,' providing insight into their eMSS experience. Result To date, CTA has been conducted with 6 MSS trainers, and 2 patient/partner dyads that completed the MSS training program. Early results provide insight on strengths, challenges and opportunities to optimize the eMSS. Participants could identify and use key features (e.g., menus) and found the symbols and language consistent. However, participants didn’t notice some features (e.g., interactive arrows to navigate across dates) and requested more ‘cueing’ or ‘interactive prompts.’ Participants would prefer to see all information entered on individual pages (which is possible with the MSS) to support better situation awareness. Conclusion To respond to the everyday planning needs of individuals with MCI in a digital age, an eMSS was developed, drawing on a clinically trialed hardcopy version (MSS). Positive feedback from MSS trainers and patients with MCI and their partners suggests promise for the overall design. Improvements for the next iteration include designing cues to help users know actions have been completed or when to attend to important information, as well as providing more fulsome information on pages to support awareness of daily tasks.
Head‐to‐head trajectories of MK6240, Flortaucipir, and plasma p ‐tau217 as a function of Aβ
Povala, Guilherme, Ferreira, Pamela C.L., Amaral, Lívia , Rocha, Andreia, Soares, Carolina, Masdeu, Joseph C. , Tudorascu, Dana , Karikari, Thomas K, Soleimani‐Meigooni, David, Fortea, Juan M., Lowe, Val J. , Oh, Hwamee , Pascual, Belén , Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Rocha, Andréia Silva da , Pascual, Belen , Bellaver, Bruna , Povala, Guilherme , Ferreira, Pâmela C.L. , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Rocha, Andreia, Soares, Carolina , Masdeu, Joseph C , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S3 | Pages: No page available

10.1002/alz70857_105968 Get It

Abstract Background Tau PET tracers present distinct binding characteristics that might influence their trajectories and relationship with other biomarkers along the AD continuum. In a head‐to‐head study, we investigated the relationship between the emergence of PET tracers MK6240 and Flortaucipir, and plasma p ‐tau217 abnormalities as a function of Aβ PET deposition. We further assessed the concordance between tau PET and plasma p ‐tau217 positivity and its relationship with cognitive scores. Method We evaluated 352 individuals from the HEAD study (205 cognitively unimpaired and 147 cognitively impaired) with Aβ PET, MK6240 and Flortaucipir tau PET, and plasma p ‐tau217 (ALZpath) and GFAP (Quanterix) measures. Tau PET Braak regions, plasma p ‐tau217 trajectories were modeled as functions of Aβ burden (Centiloid scale) using the Lowess method. Biomarkers were z‐scored anchored on young individuals ( n = 19, < 28 years old) as anchors. Tau PET (Braak 1 region) and plasma p ‐tau217 were considered positive/abnormal when surpassing 2.5 z‐score. Result Among the tested markers, MK6240 was the earliest to show abnormality as a function of Centiloid, occurring at 22 Centiloids, followed by plasma p ‐tau217 at 38 Centiloid and Flortaucipir at Centiloid 56 (Figure 1). Tau PET and plasma p ‐tau217 positivity showed an overall high concordance (∼80% for both tracers; Figure 2). In MK6240 discordant cases, most individuals were MK6240+/p‐tau217‐ (13.8%), while 6.6% were MK6240‐/p‐tau217+ (Figure 2A). For Flortaucipir, 15% of discordant cases were Flortaucipir‐/p‐tau217+, while 4.8% were Flortaucipir+/p‐tau217‐ (Figure 2B). The discordant groups present higher Centiloid than the ptau217‐/Tau‐ group and overall decreased scores in cognitive tests, except for p ‐tau217+/MK6240‐ group (Figure 3). Conclusion MK6240 becomes abnormal at lower levels of Aβ burden compared to plasma p ‐tau217 and Flortaucipir. The relatively high prevalence of discordant tau PET positive or plasma p ‐tau217 positive and suggests that some individuals may show tau PET positivity first, while others may exhibit plasma p ‐tau217 positivity first. The distinct cognitive profiles of this groups suggest potential clinical relevance, warranting further investigation.